Clinical Trial: A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT04261439) titled 'A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab' on Feb. 6.

Brief Summary: The purpose of this phase I/Ib study is to determine the safety profile of NIZ985 (new formulation), and if it can be safely combined with Spartalizumab and to determine the appropriate dose and schedule for further study. Moreover, the study will characterize the pharmacokinetic profiles of NIZ985 as a single agent and in combination with Spartalizumab and identify preliminary anti-tumor activity.

Study Type: Interventional

Condition: * In Escalation: All Patients With Solid Tumors and Lymphoma

* In Expansion: Melanoma

Interventi...